DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR) (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial ...
DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of ...
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries "We are delighted with the addition of clinical sites in the EU and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results